Is Sanofi India Ltd (SANOFI) a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Sanofi India Ltd is a good quality company .

Is Sanofi India Ltd (SANOFI) undervalued or overvalued?

The key valuation ratios of Sanofi India Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone .

What is Sanofi India Ltd (SANOFI) share price return in the past 10 years?

Sanofi India Ltd share price has declined -1.8% annually (CAGR) over the past ten years.

Is Sanofi India Ltd (SANOFI) a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Sanofi India Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

What is the share price of Sanofi India Ltd (SANOFI)?

Company share prices are keep on changing according to the market conditions. The current trading price of Sanofi India Ltd (SANOFI) on 17-Apr-2026 16:59:59 at 16:59 is 3559.80.

What is the P/E ratio of Sanofi India?

The latest standalone P/E ratio of Sanofi India as of 17-Apr-2026 is 25.09.

What is the P/B ratio of Sanofi India Ltd (SANOFI)?

The latest standalone P/B ratio of Sanofi India Ltd (SANOFI) as of 17-Apr-2026 is 12.10.

What is the 52-week high and low of Sanofi India Ltd (SANOFI)?

The 52-week high of Sanofi India Ltd (SANOFI) is Rs. 6717.50 and the 52-week low is Rs. 3151.05.

Sanofi India Ltd (SANOFI) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Sanofi India Ltd (SANOFI)
Brand: Sanofi India

Key Metrics

Market Cap

₹8,198 Cr.

P/E Ratio

25.09

Price to Book (P/B)

12.10

Price to Sales (P/S)

4.46

EV/EBITDA

15.51

Return on Capital Employed (ROCE)

55.46%

Current Price

₹3,559.8

Return on Equity (ROE)

44.50%

Return on Assets (ROA)

7.18%

Operating Profit Margin

26.7%

Net Profit Margin

17.78%

Gross Profit Margin

24.5%

Book Value per Share

₹294.1

Sales Growth (YoY)

-8.73%

Sales Growth (3 Years)

-12.79%

Operating Profit Growth (1 Year)

0.2%

Operating Profit Growth (3 Years)

-11.25%

Net Profit Growth (1 Year)

4.14%

52-Week Low / High

₹3,151 / 6,718

Net Profit Growth (3 Years)

-19.26%

Dividend Yield

3.01%

Promoter Holding

60.40%

Pledged shares (%)
of Promoter's holding (%)

0.00%

Check Before You Invest

Q.1 Revenue growth of Sanofi India Ltd?

Sanofi India Ltd revenue growth is -8.7% for FY-2025 , which is in line with its 5 year CAGR of -8.7% , indicating stable growth.

Q.1 Promoter shareholding and pledge status of Sanofi India Ltd?

Promoters hold 60.40% of the Sanofi India Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Revenue growth of Sanofi India Ltd vs industry peers?

Sanofi India Ltd revenue CAGR is -8.74% , compared to the industry median CAGR of 5.54% , indicating slower growth and losing its market share.

Q.1 Which industry/sub-sector does Sanofi India Ltd belong to?

Sanofi India Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.

Q.1 Stock return of Sanofi India Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of -1.9% based on the current price.

DeciZen - make an informed investing decision on Sanofi India

Based on:

Data

Overall Rating ⓘ
Login to view analysis.

1. Quality

2. Valuation

3. Price Trend

Sanofi India stock performance

Key Ratios

Is Sanofi India Ltd an attractive stock to invest in?

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Dec'16	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
ROCE % ⓘ	27.5%	26.4%	28.8%	25.8%	29.8%	58%	49.5%	46.3%	46.2%	55.5%	-
Value Creation Index ⓘ	1.0	1.0	1.1	0.9	1.2	3.3	2.7	2.4	2.4	3.1	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	2,367	2,464	2,771	3,071	2,902	2,957	2,770	1,996	2,013	1,837	1,837
Sales YoY Gr.	-	4.1%	12.5%	10.8%	-5.5%	1.9%	-6.3%	-27.9%	0.9%	-8.7%	-
Adj EPS ⓘ	131.3	139.9	163.5	197.9	220.9	259.2	229.4	153.1	146.9	149.6	141.9
YoY Gr.	-	6.6%	16.8%	21.1%	11.6%	17.4%	-11.5%	-33.3%	-4.1%	1.9%	-
BVPS (₹) ⓘ	810.7	869.9	950.2	1,043.5	897.8	941.5	527.7	411.8	344	294.5	294.1
Adj Net Profit ⓘ	302	322	377	456	509	597	528	352	338	344	327
Cash Flow from Ops. ⓘ	322	435	374	412	611	559	399	231	462	438	-
Debt/CF from Ops. ⓘ	0	0	0	0	0	0	0	0	0	0	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	-2.8%	-8.7%	-12.8%	-8.7%
Adj EPS ⓘ	1.5%	-7.5%	-13.3%	1.9%
BVPSⓘ	-10.6%	-20%	-17.7%	-14.4%
Share Price	-1.8%	-15.1%	-15.7%	-42.8%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Dec'16	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Return on Equity % ⓘ	17.2	16.5	17.7	19.6	22.3	27.5	30.2	30.8	36.1	42.8	48.2
Op. Profit Mgn % ⓘ	22.6	21.9	22.6	21.7	24.7	25.8	25.4	24.5	24.4	26.7	26.7
Net Profit Mgn % ⓘ	12.8	13.1	13.6	14.9	17.5	20.2	19.1	17.7	16.8	18.8	17.8
Debt to Equity ⓘ	0	0	0	0	0	0	0	0	0	0	0
Working Cap Days ⓘ	156	287	379	386	419	436	446	656	661	692	86
Cash Conv. Cycle ⓘ	50	31	20	18	13	2	-3	48	32	9	36

Recent Performance Summary

Latest Financials

	Standalone	Consolidated
TTM EPS (₹)	141.9	179.5
TTM Sales (₹ Cr.)	1,837	2,013
BVPS (₹) ⓘ	294.1	343.5
Reserves (₹ Cr.) ⓘ	654	768
P/BV ⓘ	12.10	10.36
PE ⓘ	25.09	19.84

From the Market
52 Week Low / High (₹)	3151.05 / 6717.50
All Time Low / High (₹)	235.05 / 10526.05
Market Cap (₹ Cr.)	8,198
Equity (₹ Cr.)	23
Face Value (₹)	10
Industry PE ⓘ	42.1

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Sanofi India - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Key Ratios

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Dec'16	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Sales	2,367	2,464	2,771	3,071	2,902	2,957	2,770	1,996	2,013	1,837
Operating Expenses ⓘ +	1,832	1,926	2,148	2,405	2,189	2,194	2,067	1,509	1,523	1,346
Manufacturing Costs	121	120	144	142	114	88	84	34	45	37
Material Costs	1,065	1,004	1,146	1,347	1,254	1,307	1,190	954	979	897
Employee Cost	355	369	407	450	461	434	406	281	240	185
Other Costs ⓘ	290	434	451	466	361	366	387	241	258	227
Operating Profit ⓘ	535	537	623	665	713	762	703	487	490	491
Operating Profit Margin (%)	22.6%	21.8%	22.5%	21.7%	24.6%	25.8%	25.4%	24.4%	24.4%	26.7%
Other Income ⓘ +	66	81	90	94	90	75	73	62	17	20
Exceptional Items ⓘ	0	0	0	-59	-42	489	132	18	-38	-27
Interest ⓘ	2	1	1	0	2	2	2	2	2	2
Depreciation ⓘ	119	102	103	100	82	67	42	37	37	37
Profit Before Tax ⓘ	480	515	610	600	677	1,258	864	529	431	445
Tax ⓘ	176	189	229	186	200	313	244	164	118	118
Profit After Tax	304	326	381	414	478	944	621	365	314	327
PAT Margin (%)	12.9%	13.2%	13.7%	13.5%	16.5%	31.9%	22.4%	18.3%	15.6%	17.8%
Adjusted EPS (₹)	132.3	141.7	165.5	180.1	207.7	410.6	269.8	158.5	136.4	142.0
Dividend Payout Ratio (%)	51%	50%	51%	194%	176%	119%	211%	105%	86%	87%

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Dec'16	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Equity and Liabilities
Shareholders Fund +	1,865	2,001	2,186	2,400	2,065	2,166	1,214	947	791	677
Share Capital ⓘ	23	23	23	23	23	23	23	23	23	23
Reserves ⓘ	1,842	1,978	2,163	2,377	2,042	2,143	1,191	924	768	654
Debt +	0	0	0	0	0	0	0	0	0	0
Long Term Debt	0	0	0	0	0	0	0	0	0	0
Short Term Debt	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	231	327	344	369	318	377	356	292	406	194
Others Liabilities ⓘ	446	1,996	2,240	2,471	2,710	3,013	3,258	3,465	3,482	3,552
Total Liabilities ⓘ	2,541	4,324	4,769	5,240	5,093	5,555	4,828	4,703	4,679	4,423
Fixed Assets
Net Fixed Assets ⓘ +	817	769	733	499	464	334	306	315	313	304
Gross Block	936	989	1,053	817	852	546	531	544	568	589
Accumulated Depreciation	119	220	321	318	388	212	225	229	255	285
CWIP ⓘ	34	30	21	17	10	13	24	16	18	12
Investments ⓘ	0	0	0	0	0	0	0	2	0	0
Inventories	493	416	483	470	368	392	408	664	500	312
Trade Receivables	145	195	158	224	148	143	129	132	230	177
Cash Equivalents	561	730	832	1,130	1,209	1,550	1,017	405	295	275
Others Assets ⓘ	492	2,184	2,542	2,901	2,895	3,123	2,945	3,170	3,324	3,344
Total Assets ⓘ	2,541	4,324	4,769	5,240	5,093	5,555	4,828	4,703	4,679	4,423

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Dec'16	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Cash Flow From Operating Activity ⓘ +	322	435	374	412	611	559	399	231	462	438
PBT ⓘ	480	515	610	600	677	1,258	864	846	563	445
Adjustment ⓘ	61	39	36	78	65	-482	-159	-25	25	29
Changes in Working Capital ⓘ	-1	80	-28	-38	62	68	-46	-349	-29	72
Tax Paid ⓘ	-218	-198	-244	-228	-193	-285	-261	-241	-97	-107
Cash Flow From Investing Activity ⓘ +	-155	-79	-73	66	276	631	651	36	-19	-11
Capex	-69	-57	-57	-75	-41	-13	13	-10	-36	-25
Net Investments	0	0	0	0	0	0	0	0	0	0
Others ⓘ	-86	-22	-16	141	317	643	638	46	17	14
Cash Flow From Financing Activity ⓘ +	-180	-188	-197	-183	-810	-849	-1,583	-878	-392	-448
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	0	0	0	0	0
Interest Paid ⓘ	0	0	0	0	-2	-2	-2	-2	-2	-1
Dividend Paid ⓘ	-150	-157	-164	-152	-804	-841	-1,573	-868	-385	-442
Others ⓘ	-31	-32	-34	-31	-5	-7	-8	-8	-6	-4
Net Cash Flow ⓘ	-13	168	104	295	78	341	-533	-612	50	-21

Finance Ratio

PARTICULARS	Dec'16	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Ratios
ROE (%)	17.43	16.87	18.18	18.07	21.39	44.65	36.73	33.75	36.09	44.5
ROCE (%)	27.51	26.38	28.76	25.75	29.77	57.98	49.47	46.28	46.15	55.46
Asset Turnover Ratio	0.98	0.73	0.63	0.64	0.56	0.56	0.56	0.44	0.47	0.46
PAT to CFO Conversion(x)	1.06	1.33	0.98	1	1.28	0.59	0.64	0.63	1.47	1.34
Working Capital Days
Receivable Days	22	25	22	22	23	18	17	23	30	36
Inventory Days	73	67	57	54	53	47	50	94	96	71
Payable Days	78	101	107	97	100	97	112	124	130	122

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Sanofi India Ltd FAQs

The current trading price of Sanofi India on 17-Apr-2026 16:59 is ₹3,559.8.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 16-Apr-2026 the market cap of Sanofi India stood at ₹8,198.4 Cr

The latest P/E ratio of Sanofi India as of 16-Apr-2026 is 25.09.

The latest P/B ratio of Sanofi India as of 16-Apr-2026 is 12.10.

The 52-week high of Sanofi India is ₹6,717.5 and the 52-week low is ₹3,151.1.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Sanofi India is ₹1,837 ( Cr.) .

About Sanofi India Ltd

Sanofi India is one of the entities through which Sanofi operates in India. It was incorporated in May 1956 under the name Hoechst Fedco Pharma Private Limited. Over the years, its name was changed to Hoechst Pharmaceuticals Private Limited, Hoechst India Limited, Hoechst Marion Roussel Limited and Aventis Pharma Limited. Sanofi, one of the world's leading healthcare companies, and its 100% subsidiary - Hoechst GmbH, are the major shareholders of Sanofi India Limited and together hold 60.4% of its paid-up share capital. The shares of Sanofi India Limited are quoted on the Bombay Stock Exchange and the National Stock Exchange. The company has two manufacturing sites in Ankleshwar and Goa. Sanofi India also manufactures its products through third party manufacturers. The different types of dosage forms include tablets, capsules (hard and soft), Eye/Ear drops, ampoules, vials, creams and ointments. These products are manufactured in accordance with the same quality standards as those prevalent at its own manufacturing sites for domestic consumption and for export to Russia, the Ukraine and other CIS countries.

Business area of the company

The company is dedicated to supporting people through their health challenges. It is a global biopharmaceutical company focused on human health. The company prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. The company stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

Products

Pharmaceutical products (Adenocor, Aldurazyme, AllStar, Amaryl, Apidra, Arava, Aubagio, Augeoz, Brodactam, Cardace, Caspercid, Cerezyme, Cetapin, Clexane, Cordarone, Daonil, Depakote, Fabrazyme, Fasturtec, Fludara, Frisium, Insuman, Jevtana, Lantus, Lasilactone, Lasix, Lyxumia, Metosan, M-Nem, Myoril, Myozyme, Plavix, Primacor, Renvela Sachets, Soframycin, Solian, Stilnoct, Synvisc, Targocid, Taxotere, Telsite, Thymoglobuline, Thyrogen, Toujeo, Trental, Valparin, Vinlep, Zemiglo).

Vaccines (Adacel, Avaxim, FluQuadri, Hexaxim, Imovax Polio, Menactra, Pentaxim, Shan5, Shanchol, ShanIPV, ShanTT, Shanvac-B, Stamaril, Vaxigrip)

Consumer Healthcare products (Allegra, Allegra, Allegra M, Aminofit Forte, Amino-fit, Avil, Baralgan NU, Berrycran, Buscogast, Cetgel, Collaflex, Combiflam Plus, Combiflam Suspension, Combiflam IcyHotTM, Combiflam IcyHotTM spray, CoQ 300, DePURA by Sanofi, Dulcoflex Natural, DulcoSoft Sachet, E-Cod Plus, E-Cod W, Enlarge Forte, Enterogermina, Estoven XT, Festal N, FreeFlex Forte, Icegel, Lactacyd, Macraberin M, Mega FreeFlex, Multivite Gold, Multivite Woman, Multivite CD,
Multivite-FM Omega, Novalgin NU, Phospholip TF, Primosa, Radiance H, Seacod Active, Selace Forte,
Triomega)

Milestones

2013: Sanofi India launches Combiflam Plus.
2013: Sanofi ties up with IDF, PHFI to fight against diabetes among children in India.
2013: Sanofi India inks pact with Suzlon Energy for renewable energy.
2014: Sanofi India - Diabetic Teen from Pune achieves unique feat.
2014: Sanofi partners with Emcure Pharmaceuticals for marketing and distribution of its oncology portfolio in India.
2015: Sanofi delivers 4 lakh Shan5 vaccine doses to Gwalior and Jabalpur to support the immunization of children from five pediatric diseases.
2016: Sanofi India collaborates with National Institute of Pharmaceutical Education and Research (NIPER) Kolkata, to promote academic excellence and research.
2018: Sanofi receives positive CHMP opinion for dengue vaccine.
2018: Sanofi completes its acquisition of Ablynx following the expiration of the Squeeze-out Procedure.
2019: Sanofi signs strategic deal for exclusive US over-the-counter rights to Tamiflu in Flu Care.
2020: Sanofi Completes Acquisition of Synthorx, Inc.
2020: Sanofi joins forces with U.S. Department of Health and Human Services to advance a novel coronavirus vaccine.
2020: Sanofi and Translate Bio expand collaboration to develop mRNA vaccines across all infectious disease areas.

To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Sanofi India Ltd (SANOFI) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Sanofi India Share Price